Director/PDMR Shareholding

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company was notified today that Kevin Rakin had on September 29, 2011 acquired 44,031 Shire American Depositary Shares (ADS) at a price of $93.562 each.  One ADS is equal to three Shire ordinary shares.

This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure Rules and Transparency Rules.

Tony Guthrie

Deputy Company Secretary

For further information please contact:

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.